Lung Cancer - Genetics
In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had disease control and measurable tumor...
In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...
A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
...A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
...